PRTK News and Press, Paratek Pharmaceuticals Inc. From 06/10/21

BOSTON, June 10, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...

Crestone Joins Antimicrobials Working Group PR Newswire WASHINGTON , June 8, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug r...

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) traded today at a new 52-week high of $9.68. Approximately 302,000 shares have changed hands today, as compared to an average 30-day volume of 290,000 shares. Paratek Pharmaceuticals Inc. has overhead space with shares priced $9.65, or 14.0% bel...

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) traded at a new 52-week high today of $9.96. This new high was reached on approximately average trading volume as 302,000 shares traded hands, while the average 30-day volume is approximately 290,000 shares. Paratek Pharmaceuticals Inc is a clin...

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) traded today at a new 52-week high of $9.71. Approximately 302,000 shares have changed hands today, as compared to an average 30-day volume of 290,000 shares. Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company...

Shares of Paratek Pharmaceuticals (NASDAQ: PRTK) flew nearly 20% higher on Tuesday, on an otherwise forgettable day for the stock market. There was little mystery why -- the company won another approval for its next-generation antibiotic Nuzyra. Paratek announced that the U.S. F...

Vertex Energy (VTNR) +28%.Cloudera CLDR +24% on being acquired by Clayton, Dubilier & Rice and KKR for $5.3 billion.Orbsat Corp Common Stock (OSAT) +19%.AMC Entertainment Holdings AMC +16% on raising $230.0 million.Lineage Cell Therapeutics LCTX +14% on updat...

Paratek Pharmaceuticals (PRTK) announces that the U.S. FDA has approved the company’s supplemental New Drug Application ((sNDA)) for the oral-only dosing regimen of NUZYRA for the treatment of adults with community-acquired bacterial pneumonia ((CABP)).Shares up nearly 12%&#x...

- Oral-only dosing for the Treatment of CABP Expands the Commercial Opportunity for Primary Care Promotion - Primary Care Market Opportunity for CABP Estimated at Approximately $1.5 Billion BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PR...

BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gove...